Zydus Lifesciences Limited

NSE ZYDUSLIFE.NS

Zydus Lifesciences Limited Operating Cash Flow for the year ending March 31, 2024: USD 386.99 M

Zydus Lifesciences Limited Operating Cash Flow is USD 386.99 M for the year ending March 31, 2024, a 18.29% change year over year. Operating cash flow is cash generated from the company’s regular business operations.
  • Zydus Lifesciences Limited Operating Cash Flow for the year ending March 31, 2023 was USD 327.15 M, a 18.06% change year over year.
  • Zydus Lifesciences Limited Operating Cash Flow for the year ending March 31, 2022 was USD 277.11 M, a -38.38% change year over year.
  • Zydus Lifesciences Limited Operating Cash Flow for the year ending March 31, 2021 was USD 449.73 M, a 35.27% change year over year.
  • Zydus Lifesciences Limited Operating Cash Flow for the year ending March 31, 2020 was USD 332.47 M, a -19.84% change year over year.
Key data
Date Operating Cash Flow Net Cash Used For Investing Activities Net Cash Used Provided By Financing Activities Dividends Paid
Market news
Loading...
SV Wall Street
NSE: ZYDUSLIFE.NS

Zydus Lifesciences Limited

CEO Mr. Punit Patel
IPO Date July 1, 2002
Location India
Headquarters Zydus Corporate Park
Employees 26,921
Sector Health Care
Industries
Description

Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, Europe, Latin America, the Asia Pacific, and Africa. The company operates in Pharmaceuticals and Consumer Products segments. It offers finished dosage human formulations comprising generics, branded generics, and specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; consumer wellness products; and products in the therapeutic areas of pain management, neurology, dermatology, liver diseases, and other areas. The company also provides consumer wellness products, such as Complan; EverYuth, a range of skincare products; Nycil; Glucon-D glucose powder; Nutralite; Nutralite Doodhshakti, a portfolio of dairy products; and various other products. In addition, the company offers a pipeline of biological products in the areas of oncology, autoimmune disease, nephrology, ophthalmology, inflammation, rheumatology, hepatology, infectious disease, etc. Further, it engages in the investment, animal health and veterinary, pharmacy retail, and manpower supply and administration activities. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is based in Ahmedabad, India.

Similar companies

INDUSTOWER.NS

Indus Towers Limited

USD 4.00

0.39%

SYNGENE.NS

Syngene International Limited

USD 8.61

-1.79%

ALKEM.NS

Alkem Laboratories Limited

USD 58.36

0.18%

MOTHERSON.NS

Samvardhana Motherson International Limited

USD 1.63

1.77%

GLAND.NS

Gland Pharma Limited

USD 17.57

1.15%

StockViz Staff

February 1, 2025

Any question? Send us an email